Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1337 entries
Sorted by: Best Match Show Resources per page
Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study.

Current therapeutic research, clinical and experimental

Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S.
PMID: 24672118
Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002.

BACKGROUND: The Recover Study is an ongoing, prospective study designed 10 to assess toxicity associated with the use of nucleoside analogue reverse transcriptase inhibitors (NRTIs) (stavudine, zidovudine, lamivudine, didanosine, abacavir) in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART)...

Cite
Palacios R, Santos J, Camino X, et al. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005;66(2):117-29doi: 10.1016/j.curtheres.2005.04.002.
Palacios, R., Santos, J., Camino, X., Arazo, P., Torres Perea, R., Echevarrfa, S., Ribera, E., Sánchez de la Rosa, R., Moreno Guillen, S. (2005). Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Current therapeutic research, clinical and experimental, 66(2), 117-29. https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios, Rosario, et al. "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." Current therapeutic research, clinical and experimental vol. 66,2 (2005): 117-29. doi: https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002. PMID: 24672118; PMCID: PMC3964549.
Copy Download .nbib Format: NLM
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

SAGE open medicine

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M.
PMID: 28382208
SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017.

OBJECTIVE: VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients.METHODS: In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (⩾8 weeks) who needed to change...

Cite
Arathoon E, Bhorat A, Silaghi R, et al. Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE Open Med. 2017;5:2050312116686482doi: 10.1177/2050312116686482.
Arathoon, E., Bhorat, A., Silaghi, R., Crauwels, H., Lavreys, L., Tambuyzer, L., Van Baelen, B., Vanveggel, S., & Opsomer, M. (2017). Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE open medicine, 52050312116686482. https://doi.org/10.1177/2050312116686482
Arathoon, Eduardo, et al. "Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial." SAGE open medicine vol. 5 (2017): 2050312116686482. doi: https://doi.org/10.1177/2050312116686482
Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M. Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017. PMID: 28382208; PMCID: PMC5367767.
Copy Download .nbib Format: NLM
Proteome analysis of testis from infertile protein C inhibitor-deficient mice reveals novel changes in serpin processing and prostaglandin metabolism.

Electrophoresis

Yang H, Wahlmüller FC, Uhrin P, Baumgartner R, Mitulovic G, Sarg B, Geiger M, Zellner M.
PMID: 26332751
Electrophoresis. 2015 Nov;36(21):2837-2840. doi: 10.1002/elps.201500218. Epub 2015 Oct 20.

Serine protease inhibitors (serpin) have therapeutic potential in a variety of pathogenic processes, ranging from thrombosis and altered immune response to liver cirrhosis. To investigate the physiological effects of protein C inhibitor (PCI, serpinA5), its gene was inactivated in...

Cite
Yang H, Wahlmüller FC, Uhrin P, et al. Proteome analysis of testis from infertile protein C inhibitor-deficient mice reveals novel changes in serpin processing and prostaglandin metabolism. Electrophoresis. 2015;36(21):2837-2840doi: 10.1002/elps.201500218.
Yang, H., Wahlmüller, F. C., Uhrin, P., Baumgartner, R., Mitulovic, G., Sarg, B., Geiger, M., & Zellner, M. (2015). Proteome analysis of testis from infertile protein C inhibitor-deficient mice reveals novel changes in serpin processing and prostaglandin metabolism. Electrophoresis, 36(21), 2837-2840. https://doi.org/10.1002/elps.201500218
Yang, Hanjiang, et al. "Proteome analysis of testis from infertile protein C inhibitor-deficient mice reveals novel changes in serpin processing and prostaglandin metabolism." Electrophoresis vol. 36,21 (2015): 2837-2840. doi: https://doi.org/10.1002/elps.201500218
Yang H, Wahlmüller FC, Uhrin P, Baumgartner R, Mitulovic G, Sarg B, Geiger M, Zellner M. Proteome analysis of testis from infertile protein C inhibitor-deficient mice reveals novel changes in serpin processing and prostaglandin metabolism. Electrophoresis. 2015 Nov;36(21):2837-2840. doi: 10.1002/elps.201500218. Epub 2015 Oct 20. PMID: 26332751.
Copy Download .nbib Format: NLM
Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?.

BMJ open gastroenterology

Kaspar MB, Sterling RK.
PMID: 26966552
BMJ Open Gastroenterol. 2016 Mar 02;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016.

OBJECTIVE: Hyperbilirubinaemia (HB) is common in HIV and hepatitis C virus (HIV-HCV) co-infected patients and poses a unique challenge in management as it may be due to medications such as the protease inhibitors (PIs) or to hepatic dysfunction. There...

Cite
Kaspar MB, Sterling RK. Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterol. 2016;3(1):e000072doi: 10.1136/bmjgast-2015-000072.
Kaspar, M. B., & Sterling, R. K. (2016). Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ open gastroenterology, 3(1), e000072. https://doi.org/10.1136/bmjgast-2015-000072
Kaspar, Matthew B, and Sterling, Richard K. "Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?." BMJ open gastroenterology vol. 3,1 (2016): e000072. doi: https://doi.org/10.1136/bmjgast-2015-000072
Kaspar MB, Sterling RK. Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterol. 2016 Mar 02;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016. PMID: 26966552; PMCID: PMC4780040.
Copy Download .nbib Format: NLM
A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Journal of clinical and experimental hepatology

Naik GS, Tyagi MG.
PMID: 25755405
J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12.

Chronic hepatitis C (CHC) infection, usually an asymptomatic infection, has long-term serious complications such as cirrhosis, hepatocellular carcinoma, and end-stage liver disease requiring liver transplantation (LT). Several novel drugs against hepatitis C which form part of 'specifically targeted antiviral...

Cite
Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol. 2012;2(1):42-54doi: 10.1016/S0973-6883(12)60090-5.
Naik, G. S., & Tyagi, M. G. (2012). A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. Journal of clinical and experimental hepatology, 2(1), 42-54. https://doi.org/10.1016/S0973-6883(12)60090-5
Naik, Girish S, and Tyagi, Manoj G. "A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection." Journal of clinical and experimental hepatology vol. 2,1 (2012): 42-54. doi: https://doi.org/10.1016/S0973-6883(12)60090-5
Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12. PMID: 25755405; PMCID: PMC3940409.
Copy Download .nbib Format: NLM
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation.

Patient related outcome measures

Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C.
PMID: 25733942
Patient Relat Outcome Meas. 2015 Feb 17;6:53-60. doi: 10.2147/PROM.S63586. eCollection 2015.

OBJECTIVES: Costs may play a role in deciding how and when to start highly active antiretroviral therapy (HAART) in a naïve patient. The aim of the present study was to assess the cost- effectiveness of treatment with HAART in...

Cite
Maggiolo F, Colombo GL, Di Matteo S, et al. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas. 2015;6:53-60doi: 10.2147/PROM.S63586.
Maggiolo, F., Colombo, G. L., Di Matteo, S., Bruno, G. M., Astuti, N., Di Filippo, E., Masini, G., & Bernardini, C. (2015). Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient related outcome measures, 653-60. https://doi.org/10.2147/PROM.S63586
Maggiolo, Franco, et al. "Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation." Patient related outcome measures vol. 6 (2015): 53-60. doi: https://doi.org/10.2147/PROM.S63586
Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas. 2015 Feb 17;6:53-60. doi: 10.2147/PROM.S63586. eCollection 2015. PMID: 25733942; PMCID: PMC4337626.
Copy Download .nbib Format: NLM
Hepatitis C genotype 4: The past, present, and future.

World journal of hepatology

Abdel-Ghaffar TY, Sira MM, El Naghi S.
PMID: 26668691
World J Hepatol. 2015 Dec 08;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792.

Hepatitis C virus (HCV) genotype (GT) 4 represents 12%-15% (15-18 million) of total global HCV infection. It is prevalent in Northern and Equatorial Africa and the Middle East, and is also present in some countries in Europe. GT-4 (and...

Cite
Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015;7(28):2792-810doi: 10.4254/wjh.v7.i28.2792.
Abdel-Ghaffar, T. Y., Sira, M. M., & El Naghi, S. (2015). Hepatitis C genotype 4: The past, present, and future. World journal of hepatology, 7(28), 2792-810. https://doi.org/10.4254/wjh.v7.i28.2792
Abdel-Ghaffar, Tawhida Y, et al. "Hepatitis C genotype 4: The past, present, and future." World journal of hepatology vol. 7,28 (2015): 2792-810. doi: https://doi.org/10.4254/wjh.v7.i28.2792
Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015 Dec 08;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792. PMID: 26668691; PMCID: PMC4670951.
Copy Download .nbib Format: NLM
Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study.

AIDS research and therapy

Meintjes G, Dunn L, Coetsee M, Hislop M, Leisegang R, Regensberg L, Maartens G.
PMID: 26628902
AIDS Res Ther. 2015 Dec 01;12:39. doi: 10.1186/s12981-015-0081-8. eCollection 2015.

BACKGROUND: An increasing number of patients in Africa are experiencing virologic failure on second-line antiretroviral therapy (ART) and those who develop resistance to protease inhibitors (PI) will require third-line ART, but no data on the outcomes of third-line are...

Cite
Meintjes G, Dunn L, Coetsee M, et al. Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Res Ther. 2015;12:39doi: 10.1186/s12981-015-0081-8.
Meintjes, G., Dunn, L., Coetsee, M., Hislop, M., Leisegang, R., Regensberg, L., & Maartens, G. (2015). Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS research and therapy, 1239. https://doi.org/10.1186/s12981-015-0081-8
Meintjes, Graeme, et al. "Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study." AIDS research and therapy vol. 12 (2015): 39. doi: https://doi.org/10.1186/s12981-015-0081-8
Meintjes G, Dunn L, Coetsee M, Hislop M, Leisegang R, Regensberg L, Maartens G. Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Res Ther. 2015 Dec 01;12:39. doi: 10.1186/s12981-015-0081-8. eCollection 2015. PMID: 26628902; PMCID: PMC4666151.
Copy Download .nbib Format: NLM
Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection.

World journal of clinical cases

Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP.
PMID: 28255546
World J Clin Cases. 2017 Feb 16;5(2):40-45. doi: 10.12998/wjcc.v5.i2.40.

A 54-year-old black African woman, 22 years human immunodeficiency virus (HIV)-positive, presented with an acute coronary syndrome. She was taking two nucleoside reverse transcriptase inhibitors and two protease inhibitors. Viral load and CD4 count were stable. Angiography revealed a...

Cite
Alkhalil M, Conlon CP, Ashrafian H, et al. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases. 2017;5(2):40-45doi: 10.12998/wjcc.v5.i2.40.
Alkhalil, M., Conlon, C. P., Ashrafian, H., & Choudhury, R. P. (2017). Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World journal of clinical cases, 5(2), 40-45. https://doi.org/10.12998/wjcc.v5.i2.40
Alkhalil, Mohammad, et al. "Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection." World journal of clinical cases vol. 5,2 (2017): 40-45. doi: https://doi.org/10.12998/wjcc.v5.i2.40
Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases. 2017 Feb 16;5(2):40-45. doi: 10.12998/wjcc.v5.i2.40. PMID: 28255546; PMCID: PMC5314259.
Copy Download .nbib Format: NLM
Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization.

Tetrahedron letters

Ghosh AK, Xu CX, Osswald HL.
PMID: 26185337
Tetrahedron Lett. 2015 Jun 03;56(23):3314-3317. doi: 10.1016/j.tetlet.2015.01.019.

Synthesis of novel HIV-1 protease inhibitors incorporating dioxatriquinane-derived P2-ligands is described. The tricyclic ligand alcohol contains five contiguous chiral centers. The ligand alcohols were prepared in optically active form by an enzymatic asymmetrization of mesodiacetate, cascade radical cyclization, and...

Cite
Ghosh AK, Xu CX, Osswald HL. Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization. Tetrahedron Lett. 2015;56(23):3314-3317doi: 10.1016/j.tetlet.2015.01.019.
Ghosh, A. K., Xu, C. X., & Osswald, H. L. (2015). Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization. Tetrahedron letters, 56(23), 3314-3317. https://doi.org/10.1016/j.tetlet.2015.01.019
Ghosh, Arun K, et al. "Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization." Tetrahedron letters vol. 56,23 (2015): 3314-3317. doi: https://doi.org/10.1016/j.tetlet.2015.01.019
Ghosh AK, Xu CX, Osswald HL. Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization. Tetrahedron Lett. 2015 Jun 03;56(23):3314-3317. doi: 10.1016/j.tetlet.2015.01.019. PMID: 26185337; PMCID: PMC4500529.
Copy Download .nbib Format: NLM
PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread.

Nanoscale research letters

Tang X, Liang Y, Liu X, Zhou S, Liu L, Zhang F, Xie C, Cai S, Wei J, Zhu Y, Hou W.
PMID: 26489856
Nanoscale Res Lett. 2015 Dec;10(1):413. doi: 10.1186/s11671-015-1112-z. Epub 2015 Oct 22.

Activating HIV-1 proviruses in latent reservoirs combined with inhibiting viral spread might be an effective anti-HIV therapeutic strategy. Active specific delivery of therapeutic drugs into cells harboring latent HIV, without the use of viral vectors, is a critical challenge...

Cite
Tang X, Liang Y, Liu X, et al. PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread. Nanoscale Res Lett. 2015;10(1):413doi: 10.1186/s11671-015-1112-z.
Tang, X., Liang, Y., Liu, X., Zhou, S., Liu, L., Zhang, F., Xie, C., Cai, S., Wei, J., Zhu, Y., & Hou, W. (2015). PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread. Nanoscale research letters, 10(1), 413. https://doi.org/10.1186/s11671-015-1112-z
Tang, Xiaolong, et al. "PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread." Nanoscale research letters vol. 10,1 (2015): 413. doi: https://doi.org/10.1186/s11671-015-1112-z
Tang X, Liang Y, Liu X, Zhou S, Liu L, Zhang F, Xie C, Cai S, Wei J, Zhu Y, Hou W. PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread. Nanoscale Res Lett. 2015 Dec;10(1):413. doi: 10.1186/s11671-015-1112-z. Epub 2015 Oct 22. PMID: 26489856; PMCID: PMC4614850.
Copy Download .nbib Format: NLM
Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis.

Acute medicine & surgery

Yamamoto T, Yamamura H, Yamamoto H, Mizobata Y.
PMID: 29123791
Acute Med Surg. 2016 Jan 14;3(3):237-243. doi: 10.1002/ams2.173. eCollection 2016 Jul.

AIM: Continuous regional arterial infusion (CRAI) of protease inhibitors may be effective in the treatment of severe acute pancreatitis (SAP), but it is more invasive than i.v. infusion. The purpose of this study was to examine the effectiveness of...

Cite
Yamamoto T, Yamamura H, Yamamoto H, et al. Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis. Acute Med Surg. 2016;3(3):237-243doi: 10.1002/ams2.173.
Yamamoto, T., Yamamura, H., Yamamoto, H., & Mizobata, Y. (2016). Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis. Acute medicine & surgery, 3(3), 237-243. https://doi.org/10.1002/ams2.173
Yamamoto, Tomonori, et al. "Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis." Acute medicine & surgery vol. 3,3 (2016): 237-243. doi: https://doi.org/10.1002/ams2.173
Yamamoto T, Yamamura H, Yamamoto H, Mizobata Y. Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis. Acute Med Surg. 2016 Jan 14;3(3):237-243. doi: 10.1002/ams2.173. eCollection 2016 Jul. PMID: 29123791; PMCID: PMC5667240.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1337 entries